JFJames R. Fuchs

James R. Fuchs

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James R. Fuchs has a total of 219 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Activity of Didesmethylrocaglamide in High Grade Serous Ovarian Cancer Using Preclinical In Vitro and In Vivo Models

    by Elizabeth N. Kaweesa, Nicole Benson, Tyler A. Wilson, Ermias Mekuria Addo, Jane Miglo, Jaqueline M. Bazioli, Daniel D. Lantvit, Garima Agarwal, A. Douglas Kinghorn, James R. Fuchs, et al.

    High grade serous ovarian cancer (HGSOC) is the most lethal gynecological cause of death in women and requires new treatments to help tackle chemoresistance. Rocaglamides, a promising class of anticancer natural products, function as protein translation inhibitors and trigger apoptosis in other types of solid tumors. Didesmethylrocaglamide ((±)-DDR), a derivative of rocaglamide with potent antitumor activity, was synthesized, including three additional rocaglamide derivatives, (±)-DDR01, (±)-DDR03, and (±)-DDR04, to evaluate their cytotoxicity in HGSOC. Using in vitro models, it was determined that (±)-DDR induced cytotoxicity in ovarian cancer cell lines as early as 24 h after application and activated caspase-3, indicating pro-apoptotic activity. In addition, (±)-DDR was cytotoxic in the PE04 and MCF7-ADR (OVCAR8-RES) cell lines that are resistant to cisplatin and paclitaxel, respectively. Evaluation of each enantiomer revealed the minus enantiomer to be ∼18-fold more potent compared to the plus enantiomer in the OVCAR8 cell line. (−)-DDR was further evaluated using an OVCAR8 xenograft model in mice, and a reduction in tumor burden was observed. Its effective cytotoxicity in drug-sensitive and -resistant cell models suggests that (±)-DDR and its corresponding minus enantiomer may have potential as a new therapeutic strategy against HGSOC.


  • Open Access

    Delineating Structural Functionalities of Lenacapavir Amenable to Modifications for Targeting Emerging Drug-Resistant HIV-1 Capsid Variants

    by Daniel Adu-Ampratwum, Arun S. Annamalai, Tung Dinh, Jeffrey R. Lockwood, Ross H. Bockbrader, Reed Haney, Mamuka Kvaratskhelia, James R. Fuchs

    Lenacapavir (LEN) is a new, first-in-class, long acting, HIV-1 capsid (CA)-targeting inhibitor for treating multidrug-resistant HIV-1 infections. LEN exhibits high potency against all major HIV-1 subtypes including variants resistant to current antiretroviral therapies providing a life-saving opportunity for heavily treatment-experienced adults with multidrug-resistant HIV-1. Despite this, LEN has a relatively low barrier to viral resistance. Clinical trials identified resistance-associated mutations near LEN binding site, with the M66I variant exhibiting highest level of resistance (>3200-fold). These findings necessitate continuing efforts to develop next-generation inhibitors against emerging LEN-resistant mutation. We focused on identifying LEN structural functionalities amenable to modifications and to develop LEN analogs with improved antiviral activity against the M66I mutant. Here, we report a new LEN analog, KFA-027, with substantially improved antiviral activity (EC50 ∼ 444 nM, >20-fold) against M66I variant. Overall, these findings suggest a route for developing next-generation LEN analogs against WT and emerging drug-resistant CA mutations.


  • Open Access

    Delineating structural functionalities of lenacapavir amenable to modifications for targeting emerging drug-resistant HIV-1 capsid variants.

    by Daniel Adu-Ampratwum, Arun S. Annamalai, Tung Dinh, Jeffrey R. Lockwood, Ross H. Bockbrader, Reed Haney, Mamuka Kvaratskhelia, James R. Fuchs

    Lenacapavir (LEN, Gilead Sciences) is a recently discovered, first-in-class, long acting, and ultra-potent HIV-1 capsid (CA)-targeting inhibitor for treatment of multi-drug-resistant HIV-1 infections. LEN exhibits high potency against all major HIV-1 types including the viral variants resistant to current antiretroviral therapies. Accordingly, LEN provides a lifesaving therapy for heavily treatment-experienced adults with multi-drug-resistant HIV-1. However, one notable shortcoming is a relatively low barrier of viral resistance to LEN. The clinical trials have identified resistance-associated mutations near the LEN binding site on HIV-1 CA including M66I, Q67H/K/N, K70R/H/N/S, N74D/H/K, A105S/T and T107N/A/C/S changes. Of these, the M66I variant exhibited the highest level of resistance (>3,200-fold) to LEN. These findings necessitate continuing medicinal chemistry efforts to develop next-generation HIV-1 CA inhibitors against the emerging LEN resistant mutation. Here, our SAR studies have focused on the identification of LEN structural functionalities amenable to modifications and the development of a LEN analog with improved antiviral activity against the M66I mutant virus. We report a new LEN analog, KFA-027, with substantially improved antiviral activity (EC50 of ~444 nM, >20-fold) against HIV-1(M66I CA) compared to the parent LEN. Overall, our findings suggest a route for the future development of improved analogs against WT and emerging drug-resistant CA mutations.


  • Additional Bioactive Silvestrol Analogs from the Roots of Aglaia perviridis Collected in Vietnam

    by Ermias Mekuria Addo, Daniel Adu-Ampratwum, Elizabeth N. Kaweesa, Garima Agarwal, Dmitriy Uchenik, Tran N. Ninh, Djaja D. Soejarto, Joanna E. Burdette, James R. Fuchs, A. Douglas Kinghorn, et al.

    The tropical plant Aglaia perviridis is known to produce cyclopenta[b]benzofuran and other types of rocaglate derivatives including silvestrol (3) and 5‴-episilvestrol (4) that are of current pharmacological interest. In the present work, further investigation of A. perviridis roots collected in Vietnam has yielded two new rocaglate acetonide derivatives (1 and 2) and a known pentanor-3,4-seco-dammarane triterpenoid (7) found for the first time as a natural product, in addition to four known rocaglates (3-6). The structures of compounds 1 and 2 were confirmed by partial synthesis experiments, and their potential occurrence as extraction artifacts was investigated by targeted selective ion monitoring using UHPLC-MS. All compounds obtained were evaluated against a panel of four human cancer cell lines, in which the six rocaglate derivatives (1-6) tested all showed submicromolar potencies.


  • Open Access

    Semisynthetic derivatives of the fungal metabolite eupenifeldin via targeting the tropolone hydroxy groups

    by Zeinab Y. Al Subeh, Herma C. Pierre, Ross H. Bockbrader, Robert J. Tokarski, Amanda C. Maldonado, Monica A. Haughan, Manuel E. Rangel-Grimaldo, Cedric J. Pearce, Joanna E. Burdette, James R. Fuchs, et al.

  • Open Access

    Verticillins: fungal epipolythiodioxopiperazine alkaloids with chemotherapeutic potential

    by Herma C. Pierre, Chiraz Soumia M. Amrine, Michael G. Doyle, Amrita Salvi, Huzefa A. Raja, Jonathan R. Chekan, Andrew C. Huntsman, James R. Fuchs, Kebin Liu, Joanna E. Burdette, et al.

    Covering: 1970 through June of 2023 Verticillins are epipolythiodioxopiperazine (ETP) alkaloids, many of which possess potent, nanomolar-level cytotoxicity against a variety of cancer cell lines. Over the last decade, their in vivo activity and mode of action have been explored in detail. Notably, recent studies have indicated that these compounds may be selective inhibitors of histone methyltransferases (HMTases) that alter the epigenome and modify targets that play a crucial role in apoptosis, altering immune cell recognition, and generating reactive oxygen species. Verticillin A (1) was the first of 27 analogues reported from fungal cultures since 1970. Subsequent genome sequencing identified the biosynthetic gene cluster responsible for producing verticillins, allowing a putative pathway to be proposed. Further, molecular sequencing played a pivotal role in clarifying the taxonomic characterization of verticillin-producing fungi, suggesting that most producing strains belong to the genus Clonostachys (i.e., Bionectria), Bionectriaceae. Recent studies have explored the total synthesis of these molecules and the generation of analogues via both semisynthetic and precursor-directed biosynthetic approaches. In addition, nanoparticles have been used to deliver these molecules, which, like many natural products, possess challenging solubility profiles. This review summarizes over 50 years of chemical and biological research on this class of fungal metabolites and offers insights and suggestions on future opportunities to push these compounds into pre-clinical and clinical development.


  • Discovery and development of botanical natural products and their analogues as therapeutics for ovarian cancer

    by Brittney K. Mize, Amrita Salvi, Yulin Ren, Joanna E. Burdette, James R. Fuchs

    This review highlights botanical natural products with activity against ovarian cancer and key drug development considerations for their advancement.


  • Examination of the Impact of Triazole Position within Linkers on Solubility and Lipophilicity of a CDK9 Degrader Series

    by Oluwatosin R. Ayinde, Chia Sharpe, Emily Stahl, Robert J. Tokarski, James R. Lerma, Natarajan Muthusamy, John C. Byrd, James R. Fuchs

    Optimization of degrader properties is often a challenge due to their beyond-rule-of-5 nature. Given the paucity of known E3 ligases and the often-limited choice of ligands with varied chemical structures for a given protein target, degrader linkers represent the best position within the chimeric molecules to modify their overall physicochemical properties. In this work, a series of AT7519-based CDK9 degraders was assembled using click chemistry, facilitating the tuning of aqueous solubility and lipophilicity while retaining their linker type and molecular weight. Using chromatographic logD and kinetic solubility experiments, we show that degraders with similar chemical constitution but varied position of the embedded triazole demonstrate different lipophilicity and aqueous solubility properties. Overall, this work highlights the impact of triazole placement on linker composition through application of click chemistry for degrader synthesis and its ability to be used to promote the achievement of favorable physicochemical properties.


  • Open Access

    $\mathsf{G^2Retro}$ as a Two-Step Graph Generative Models for Retrosynthesis Prediction

    by Ziqi Chen, Oluwatosin R. Ayinde, James R. Fuchs, Huan Sun, Xia Ning

    Retrosynthesis is a procedure where a target molecule is transformed into potential reactants and thus the synthesis routes can be identified. Recently, computational approaches have been developed to accelerate the design of synthesis routes. In this paper, we develop a generative framework $\mathsf{G^2Retro}$ for one-step retrosynthesis prediction. $\mathsf{G^2Retro}$ imitates the reversed logic of synthetic reactions. It first predicts the reaction centers in the target molecules (products), identifies the synthons needed to assemble the products, and transforms these synthons into reactants. $\mathsf{G^2Retro}$ defines a comprehensive set of reaction center types, and learns from the molecular graphs of the products to predict potential reaction centers. To complete synthons into reactants, $\mathsf{G^2Retro}$ considers all the involved synthon structures and the product structures to identify the optimal completion paths, and accordingly attaches small substructures sequentially to the synthons. Here we show that $\mathsf{G^2Retro}$ is able to better predict the reactants for given products in the benchmark dataset than the state-of-the-art methods.

  • Open Access

    G2Retro as a two-step graph generative models for retrosynthesis prediction

    by Ziqi Chen, Oluwatosin R. Ayinde, James R. Fuchs, Huan Sun, Xia Ning

    Retrosynthesis is a procedure where a target molecule is transformed into potential reactants and thus the synthesis routes can be identified. Recently, computational approaches have been developed to accelerate the design of synthesis routes. In this paper,we develop a generative framework 2 for one-step retrosynthesis prediction. 2 imitates the reversed logic of synthetic reactions. It first predicts the reaction centers in the target molecules (products), identifies the synthons needed to assemble the products, and transforms these synthons into reactants. 2 defines a comprehensive set of reaction center types, and learns from the molecular graphs of the products to predict potential reaction centers. To complete synthons into reactants, 2 considers all the involved synthon structures and the product structures to identify the optimal completion paths, and accordingly attaches small substructures sequentially to the synthons. Here we show that 2 is able to better predict the reactants for given products in the benchmark dataset than the state-of-the-art methods.